Liver transplantation for hepatocellular carcinoma: the Japanese experience
- PMID: 19763387
- DOI: 10.1007/s00534-009-0168-5
Liver transplantation for hepatocellular carcinoma: the Japanese experience
Abstract
Despite the wide spectrum of selection criteria used by living donor liver transplantation (LDLT) centers in Japan, LDLT for hepatocellular carcinoma (HCC) can achieve an acceptable outcome comparable to the outcome for deceased donor liver transplantation (DDLT) for HCC. One of the most crucial considerations in liver transplantation for HCC is the advent of expanded criteria that allow more patients with HCC to receive the organs and offer similar or even better results compared to the Milan of UCSF criteria. Expanded criteria for HCC are proposed from three single-center and one multicenter study in Japan. These criteria are based on the independent predictors for outcome derived from the analyses of the pretransplant factors and explant pathology. The beneficial effect of those proposed criteria can be predicted by the inclusion rates of the patients compared to the Milan or UCSF criteria in the same cohort and the outcome for those included patients. While application of the UCSF criteria increases the inclusion rate compared to the Milan criteria by 5-10%, these proposed criteria increase the inclusion rates by 5-54% compared to the Milan criteria. The higher inclusion rates compared to the application of the Milan criteria are achieved by criteria including tumor markers, either AFP or PIVKA II or both. Inclusion of tumor markers in addition to parameters of tumor morphology might be the key to establish the best criteria for liver transplantation for HCC.
Similar articles
-
Living donor liver transplantation for hepatocellular carcinoma.Recent Results Cancer Res. 2013;190:165-79. doi: 10.1007/978-3-642-16037-0_11. Recent Results Cancer Res. 2013. PMID: 22941020
-
Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience.Transplantation. 2014 Apr 27;97 Suppl 8:S20-3. doi: 10.1097/01.tp.0000446269.20934.d3. Transplantation. 2014. PMID: 24849825
-
Comparative study of living and deceased donor liver transplantation as a treatment for hepatocellular carcinoma.J Am Coll Surg. 2015 Mar;220(3):297-304.e3. doi: 10.1016/j.jamcollsurg.2014.12.009. Epub 2014 Dec 13. J Am Coll Surg. 2015. PMID: 25617912
-
Liver transplantation for hepatocellular carcinoma: Korean experience.J Hepatobiliary Pancreat Sci. 2010 Sep;17(5):539-47. doi: 10.1007/s00534-009-0167-6. Epub 2009 Sep 2. J Hepatobiliary Pancreat Sci. 2010. PMID: 19727542 Review.
-
Expansion of the criteria for living donor liver transplantation for hepatocellular carcinoma.Curr Opin Organ Transplant. 2016 Apr;21(2):231-7. doi: 10.1097/MOT.0000000000000294. Curr Opin Organ Transplant. 2016. PMID: 26918880 Review.
Cited by
-
Validated model for prediction of recurrent hepatocellular carcinoma after liver transplantation in Asian population.World J Gastrointest Oncol. 2019 Apr 15;11(4):322-334. doi: 10.4251/wjgo.v11.i4.322. World J Gastrointest Oncol. 2019. PMID: 31040897 Free PMC article.
-
Evaluation of eligibility criteria in living donor liver transplantation for hepatocellular carcinoma by α-SMA-positive cancer-associated fibroblasts.Oncol Rep. 2013 Oct;30(4):1561-74. doi: 10.3892/or.2013.2616. Epub 2013 Jul 16. Oncol Rep. 2013. PMID: 23863893 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical